VIGONVITA-B

Established in 2013, Suzhou Wangshan Wangshui CNI Biomedicine Index Co., Ltd. (“Wangshan Wangshui” for short) is a comprehensive and integrated CNI Biomedicine Index company dedicated to the discovery, development and commercialization of innovative small molecule drugs. The company is committed to meeting clinical needs in the fields of viral infections, neuropsychiatry and reproductive health. The company's founder team is from the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences. They are famous scientists in the field of drug development and have more than 20 years of industry experience. The executive team has an average of 17 years of industry-related or professional management experience. The company has built end-to-end capabilities covering the entire “research-clinical-development-manufacturing-commercialization” industrial value chain. Wangshan Wangshui has formed a highly competitive and diversified pipeline of innovative pharmaceutical products. Two of them are commercialized or near commercialization, four are in the clinical stage, and three are in the pre-clinical stage. Mindvy (R&D code: VV116) was approved for marketing in Uzbekistan in December 2021 for the treatment of moderate and severe COVID-19 infections. Mindevil (R&D code: VV116) was conditionally approved for marketing by China's State Drug Administration in January 2023, and changed from conditional approval to routine approval in January 2025 for the treatment of mild to moderate COVID-19 infections. Phase II clinical trials of VV116 for the treatment of respiratory syncytial virus (RSV) infections are ongoing. TPN171 was approved for marketing in Uzbekistan in September 2022. The trade name is Onvita. It was approved for Commodity in China in July 2025. The trade name is Onvidia, and the approved indications are all male erectile dysfunction (ED). Wangshan Wangshui has established commercial production facilities that meet GMP standards in Lianyungang City, Jiangsu Province, with a total construction area of about 51,955 square meters and an annual design production capacity of 100 million capsules and 600 million tablets. Wangshan Wangshui has 81 authorized patents, and has received honors such as a national high-tech enterprise, a national specialized and innovative “little giant” enterprise, a technology-based small and medium-sized enterprise in Jiangsu Province, and a potential unicorn enterprise in Jiangsu Province. Wangshan Wangshui will continue to uphold the concept of innovation-driven development, persist in innovation, and strive to improve the health and quality of life of all patients in China and around the world.